安罗替尼联合EGFR-TKI治疗NSCLC的研究进展

Research Progress of Anlotinib Combined with EGFR-TKI in the Treatment of NSCLC

摘要: 肺癌作为全球发病率最高的癌症之一，其最常见的组织学分型为非小细胞肺癌。安罗替尼作为我国独立研究开发的新型酪氨酸激酶抑制剂，其主要作用机制包括抗血管生成及抑制肿瘤细胞增殖这两方面。中国国家药品监督管理局于2018年正式批准该药上市，可以用于治疗晚期或转移性非小细胞肺癌。近年来，关于安罗替尼治疗晚期非小细胞肺癌的临床前研究或真实世界研究层出不穷，其无论是单药还是与其他药物联合治疗，均取得了一定的研究进展。本文就安罗替尼的作用机制、单药及联合表皮生长因子酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI)的研究进展及安全性进行综述，旨在为临床用药提供更多依据。

Abstract: As one of the most common cancers worldwide, lung cancer has non-small cell lung cancer (NSCLC) as its most frequent histological type. Anlotinib, a novel tyrosine kinase inhibitor independently developed in China, mainly exerts its effects through anti-angiogenesis and inhibition of tumor cell proliferation. The National Medical Products Administration of China officially approved its marketing in 2018, and it can be used for the treatment of advanced or metastatic NSCLC. In recent years, preclinical and real-world studies on the treatment of advanced NSCLC with anlotinib have emerged in abundance. Whether used alone or in combination with other drugs, it has achieved certain research progress. This article reviews the mechanism of action of anlotinib, its research progress and safety when used alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), aiming to provide more evidence for clinical application.